Amplia Therapeutics (ASX:ATX) has delivered an update on its clinical progress, announcing an additional confirmed partial tumour response in its ACCENT trial and presenting new data to investors that reinforce the potential of its FAK inhibitor narmafotinib in metastatic pancreatic cancer. …
Amplia reports new rumour response for narmafotinib in pancreatic cancer
December 14, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 4 September
September 4, 2026 - - Podcast -
A three-pronged expansion of Commonwealth reach in therapeutic-goods regulation
September 4, 2026 - - Latest News -
If the government gives itself more power, don't be surprised when they use it
September 4, 2026 - - Latest News -
Medicines Australia calls for doubling of PBS medicines investment
September 4, 2026 - - Latest News -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - - Latest News -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - - Latest News